HR+/HER2- Metastatic Breast Cancer: Patient Profiling for Systemic Therapy

Dr. Rodrigo Sanchez-Bayona presented a clinical case of a 61-year-old postmenopausal woman with stage 4 luminal breast cancer, discussing her initial treatment with letrozole plus ribociclib, subsequent disease progression, and the decision to switch to fulvestrant plus everolimus based on biomarker testing.

Target Audience

Healthcare Professionals 

Learning Objectives

  • Analyze the role of molecular profiling and genetic testing in developing individualized treatment plans.
  • Integrate patient factors (such as age, comorbidities, and biomarker status) into personalized treatment decisions.
  • Understand the importance of patient selection factors and their impact on defining the best treatment alternative during the patient journey.
  • Balance multiple factors (pathological, clinical, and molecular) to optimally select the best treatment for each patient.

This activity is supported by an educational grant from Eli Lilly.

Course summary

Course opens: 
09/08/2026
Course expires: 
09/30/2031
Cost:
$0.00
Rating: 
0
Dr. Rodrigo Sánchez-Bayona,MD PhD

Dr. Rodrigo Sánchez-Bayona,MD PhD

Unidad de Cáncer de Mama y Ginecológico
Hospital 12 de Octubre
ESMO Young Oncologists Committee member

Price

Cost:
$0.00
Please login or register to take this course.